Contact

Our portfolio

AviSia Therapeutics

Harnessing the power of glycan-mediated immune modulation, AviSia Therapeutics develops antigen-specific immunotherapies for the treatment of autoimmune diseases. The company’s initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.

  • Institute: Amsterdam UMC
Industry: Immunology, Therapeutics
  • Founding year: 2024
Visit website

Want to get in contact about AviSia Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.

Cellagenics

Cellagenics
Scaling up therapeutic antibody production with STEP® technology.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.

Cellagenics

Cellagenics
Scaling up therapeutic antibody production with STEP® technology.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
Explore full AAV portfolio
Contact